Project Grant R21HL186484
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...
- The National Heart, Lung, and Blood Institute awarded $2.609 million to Vanderbilt University Medical Center on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathophysiological mechanisms of mitochondrial cyclophilin D acetylation in vascular dysfunction and hypertension through September 29, 2028. The project will define cell-specific pathogenic mechanisms of endothelial and smooth muscle cyclophilin D acetylation in hypertension and vascular...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $271,938 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion targeted for July 31, 2027. The grant funds a comprehensive research analysis to determine the prevalence, timing, and risk factors associated with Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) in...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received $874,997 in federal funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project grant awarded on September 15, 2025, with completion targeted by August 31, 2026. The project delivers a prospective clinical trial evaluating personalized oxygen therapy targets for mechanically ventilated critically ill adults. The research applies...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $1.732 million on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop ENT-verticilide, a selective ryanodine receptor type 2 (RYR2) inhibitor, as a novel antiarrhythmic drug for atrial fibrillation treatment. The research addresses the clinical challenge that current antiarrhythmic therapies fail frequently due to heterogeneity in underlying causes of atrial...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $767,953 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomimetic engineered heart valve leaflets that improve function and tissue remodeling. Work extends through March 31, 2030, and is performed in Pittsburgh, Pennsylvania. The project addresses clinical failures in tissue-engineered heart valves (TEHVs) deployed in pediatric patients, where pulmonary...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received $813,284 in funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 18, 2025, with completion targeted for May 31, 2030. The project will conduct a prospective mechanistic study of acute kidney injury (AKI)-associated delirium following cardiac surgery (CS-AKI-DELIRIUM), involving 300 adults undergoing on-pump coronary...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $149,904 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lymphatic-stromal interactions in fibrosis development following upper airway injury. The award funds research into laryngotracheal stenosis (LTS), a life-threatening fibrosis of the proximal airway that develops after mucosal injury from endotracheal intubation. The work addresses a gap in...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University $577,334 on July 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a sensory airway stent for continuous monitoring of airway conditions. The recipient is creating a sensor-integrated airway stent (SAS) equipped with flexible sensors and a wearable magnetic actuation unit designed to monitor stent patency and airway health in the central airway. The innovation addresses central airway...
The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $471,280 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate in silico and in vitro modeling platforms for comparing surgical repair strategies in atrioventricular septal defects (AVSD). The research will create matched computational and laboratory-based functional models of atrioventricular valves from AVSD patients to identify optimal surgical repair strategies and reduce long-term morbidity and mortality. Work encompasses three specific aims: development of finite element computational models of AV valve mechanical function and flow dynamics using echocardiographic and cross-sectional imaging from patients with partial, transitional, and complete AVSD; fabrication of AV valves using double-component deposition methodology that replicates native valve mechanical properties; and in vitro validation of valve performance metrics using a pulse-duplicator system. The project runs through July 31, 2028, and is performed at Vanderbilt University Medical Center in Forest Hills, Tennessee. This is a project grant, the primary assistance type for investigator-initiated research under the NHLBI program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $471.3k | 8/10/26 |